Share-based Payment Arrangement, Expense of Traws Pharma, Inc. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Traws Pharma, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • Traws Pharma, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $135,000, a 61% decline year-over-year.
  • Traws Pharma, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $735,000, a 47% decline year-over-year.
  • Traws Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,390,000, a 6.8% increase from 2023.
  • Traws Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,301,000, a 13% increase from 2022.
  • Traws Pharma, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,155,000, a 101% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Traws Pharma, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $735,000 $135,000 -$208,000 -61% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $943,000 $105,000 -$275,000 -72% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $1,218,000 $161,000 -$172,000 -52% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $1,390,000 $334,000 +$2,000 +0.6% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $1,388,000 $343,000 -$17,000 -4.7% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $1,405,000 $380,000 +$107,000 +39% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $1,298,000 $333,000 -$3,000 -0.89% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $1,301,000 $332,000 +$3,000 +0.91% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $1,298,000 $360,000 +$71,000 +25% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,227,000 $273,000 +$32,000 +13% 01 Apr 2023 30 Jun 2023 10-Q 15 Aug 2024 2024 Q2
Q1 2023 $1,195,000 $336,000 +$40,000 +14% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $1,155,000 $329,000 +$60,000 +22% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 $1,095,000 $289,000 +$107,000 +59% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $988,000 $241,000 +$181,000 +302% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $807,000 $296,000 +$231,000 +355% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $576,000 $269,000 +$175,000 +186% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $401,000 $182,000 +$92,000 +102% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $309,000 $60,000 -$32,000 -35% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $341,000 $65,000 -$28,000 -30% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q4 2020 $369,000 $94,000 -$4,000 -4.1% 01 Oct 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
Q3 2020 $373,000 $90,000 -$55,000 -38% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $428,000 $92,000 -$63,000 -41% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $491,000 $93,000 -$557,000 -86% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1
Q4 2019 $1,048,000 $98,000 -$214,000 -69% 01 Oct 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q3 2019 $1,262,000 $145,000 -$150,000 -51% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $1,412,000 $155,000 -$56,000 -27% 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $1,468,000 $650,000 +$372,000 +134% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q4 2018 $1,096,000 $312,000 -$65,000 -17% 01 Oct 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
Q3 2018 $1,161,000 $295,000 -$136,000 -32% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $1,297,000 $211,000 -$233,000 -52% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $1,530,000 $278,000 -$180,000 -39% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019 2019 Q1
Q4 2017 $1,710,000 $377,000 -$195,000 -34% 01 Oct 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
Q3 2017 $1,905,000 $431,000 -$145,000 -25% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $2,050,000 $444,000 -$167,000 -27% 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 $2,217,000 $458,000 -$1,712,000 -79% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q4 2016 $3,929,000 $572,000 -$236,000 -29% 01 Oct 2016 31 Dec 2016 10-K 16 Mar 2018 2017 FY
Q3 2016 $4,165,000 $576,000 -$215,000 -27% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $4,380,000 $611,000 -$193,000 -24% 01 Apr 2016 30 Jun 2016 10-Q 14 Aug 2017 2017 Q2
Q1 2016 $4,573,000 $2,170,000 +$787,000 +57% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017 2017 Q1
Q4 2015 $3,786,000 $808,000 -$33,000 -3.9% 01 Oct 2015 31 Dec 2015 10-K 29 Mar 2017 2016 FY
Q3 2015 $3,819,000 $791,000 -$795,000 -50% 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3
Q2 2015 $4,614,000 $804,000 -$509,000 -39% 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016 2016 Q2
Q1 2015 $5,123,000 $1,383,000 +$55,000 +4.1% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2016 2016 Q1
Q4 2014 $5,068,000 $841,000 -$234,000 -22% 01 Oct 2014 31 Dec 2014 10-K 28 Mar 2016 2015 FY
Q3 2014 $5,302,000 $1,586,000 -$2,510,000 -61% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $7,812,000 $1,313,000 +$934,000 +246% 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $6,878,000 $1,328,000 -$1,137,000 -46% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015 2015 Q1
Q4 2013 $8,015,000 $1,075,000 01 Oct 2013 31 Dec 2013 10-K 30 Mar 2015 2014 FY
Q3 2013 $4,096,000 -$6,594,000 -62% 01 Jul 2013 30 Sep 2013 10-Q 14 Nov 2014 2014 Q3
Q2 2013 $379,000 +$276,000 +268% 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014 2014 Q2
Q1 2013 $2,465,000 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014 2014 Q1
Q3 2012 $10,690,000 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q3
Q2 2012 $103,000 01 Apr 2012 30 Jun 2012 10-Q 06 Sep 2013 2013 Q2

Traws Pharma, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,390,000 +$89,000 +6.8% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $1,301,000 +$146,000 +13% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $1,155,000 +$579,000 +101% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 $576,000 +$207,000 +56% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023 2022 FY
2020 $369,000 -$679,000 -65% 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2022 2021 FY
2019 $1,048,000 -$48,000 -4.4% 01 Jan 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
2018 $1,096,000 -$614,000 -36% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
2017 $1,710,000 -$2,219,000 -56% 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
2016 $3,929,000 +$143,000 +3.8% 01 Jan 2016 31 Dec 2016 10-K 16 Mar 2018 2017 FY
2015 $3,786,000 -$1,282,000 -25% 01 Jan 2015 31 Dec 2015 10-K 29 Mar 2017 2016 FY
2014 $5,068,000 -$2,947,000 -37% 01 Jan 2014 31 Dec 2014 10-K 28 Mar 2016 2015 FY
2013 $8,015,000 -$5,829,000 -42% 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2015 2014 FY
2012 $13,844,000 +$13,838,000 +230633% 01 Jan 2012 31 Dec 2012 10-K 30 Mar 2015 2014 FY
2011 $6,000 01 Jan 2011 31 Dec 2011 10-K 20 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.